Vahdatpour Babak, Haghighat Shila, Sadri Leyli, Taghian Mehdi, Sadri Soroush
Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pediatric Dentistry, School of Dentistry, Mazandaran University of Medical Sciences, Mazandaran, Iran.
Galen Med J. 2022 Nov 17;11:e2407. doi: 10.31661/gmj.v11i.2407. eCollection 2022.
The use of transfer energy capacitive and resistive (TECAR) therapy to treat musculoskeletal pain has not been clearly established. Hence, this study was conducted to combine the available results. We searched the main databases, including PubMed (January 1950), Web of Knowledge (January 1945), Scopus (January 1980), and ProQuest (January 1983) until December 2021, to find the related studies. Only those studies were included that assessed the pain in participants who received TECAR therapy and compared it with a control group. Using the random effect model, standardized mean difference (SMD) was calculated at a 95% confidence interval (CI). The differences between patients and control group were -1.04 after four weeks of intervention (95% CI: -1.59 to -0.48, I=86.9%) and -1.80 after eight weeks (95% CI: -2.15 to -1.46, I=87%), which was significant (P0.001). The intra-group pain comparison before and after two, four, and eight weeks of TECAR therapy obtained SMD levels of -3.96 (95% CI: -5.28 to -2.65, I=96.9%), -4.12 (95% CI: -5.98 to -2.26, I=97.3), and -5.03 (95% CI: -7.23 to -2.83, I=92.2%), respectively. Despite some limitations, our findings may assist clinicians in decision-making about TECAR therapy for the approach to musculoskeletal pain based on evidence-based medicine.
使用转移能量电容电阻（TECAR）疗法治疗肌肉骨骼疼痛的效果尚未明确确立。因此，本研究旨在综合现有结果。我们检索了主要数据库，包括PubMed（1950年1月起）、Web of Knowledge（1945年1月起）、Scopus（1980年1月起）和ProQuest（1983年1月起），检索截至2021年12月的相关研究。仅纳入那些评估接受TECAR疗法参与者的疼痛情况并与对照组进行比较的研究。使用随机效应模型，在95%置信区间（CI）计算标准化均值差（SMD）。干预四周后患者与对照组的差异为-1.04（95%CI：-1.59至-0.48，I=86.9%），八周后为-1.80（95%CI：-2.15至-1.46，I=87%），差异具有统计学意义（P<0.001）。TECAR疗法在两周、四周和八周前后的组内疼痛比较中，SMD水平分别为-3.96（95%CI：-5.28至-2.65，I=96.9%）、-4.12（95%CI：-5.98至-2.26，I=97.3）和-5.03（95%CI：-7.23至-2.83，I=92.2%）。尽管存在一些局限性，但我们的研究结果可能有助于临床医生基于循证医学对TECAR疗法治疗肌肉骨骼疼痛的方法进行决策。
